Clinical implications of vascular growth factors in proliferative retinopathies

Current Opinion in Ophthalmology

Volumn 8, Issue 3, 1997, Pages 19-31

  Aiello, Lloyd Paul ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; GROWTH HORMONE; SOMATOMEDIN; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; DIABETIC RETINOPATHY; EYE DEVELOPMENT; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA MACULA DEGENERATION; RETINA VEIN OCCLUSION; RETROLENTAL FIBROPLASIA; REVIEW; SICKLE CELL; TREATMENT PLANNING; VISUAL IMPAIRMENT;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; GROWTH SUBSTANCES; HUMANS; LYMPHOKINES; RETINA; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030762080     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199706000-00005     Document Type: Review

References (85)

1. Michaelson IC: The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal disease. Transactions of the Ophthalmological Society of the UK 1948, 68:137-180.
2. Gartner S, Henkind P: Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol 1978, 22:291-312.
3. Henkind P: Ocular neovascularization. Am J Ophthalmol 1978, 85:287-301
4. Branch Vein Occlusion Study Group: Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. Arch Ophthalmol 1986, 104:34-41.
5. Aiello L, Wand M. Liang G: Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. Ophthalmology 1983, 90:814-820.
6. Ashton N: Retinal vascularization in health and disease. Am J Ophthalmol 1957, 44:7-24.
7. Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Ann Rev Biochem 1989, 58:575-606.
8. Vlodavsky K, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, Klagsbrun M: Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987, 84:2292-2296.
9. Montesano R, Vassali JD, Baird A, Guillemin R, Orci L: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986, 83:7297-7301.
10. Shing Y, Folkman J, Haudenschild C, Lund D, Crum R. Klagsbrun M: Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 1985, 29:275-287.
11. Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA, Gospodarowicz, D, Fiddes JC: Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986, 233:545-548.
12. Kandel J, Bossy-Wetzel E, Radvany F, Klagsbrun M, Folkman J, Hanaham D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66:1095-1104.
13. McNeil PL, Muthukrishnan L, Warder E, D'Amore PA: Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989, 109:811-822.
14. Gao H, Hollyfield JG: Basic fibroblast growth factor (bFGF) immunolocalization in the rodent outer retina demonstrated with an anti-rodent bFGF antibody. Brain Res 1992, 585:355-360.
15. Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L: Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990, 108:869-872.
16. Poulsen JE: The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953, 2:7-12.
17. Poulsen J: Diabetes and anterior pituitary insufficiency: final course and postmortem study of a diabetic patient with Sheehan's syndrome. Diabetes 1966, 15:73-77.
18. Sharp P, Fallon T, Brazier O, Sandier L, Joplin G, Kohner E: Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferate diabetic retinopathy. Diabetologia 1987, 30:199-207.
19. Merimee T: A follow-up study of vascular disease in growth hormone-deficient dwarfs with diabetes. N Engl J Med 1978, 298:1217-1222.
20. LeRoith D, Roberts CT Jr: Insulin-like growth factors. Ann NY Acad Sci 1993, 692:1-9
21. Grant MB, Guay C, Marsh R: Insulin-like growth factor I stimulates proliferation, migration and plasminogen activator release by human retinal pigment epithelial cells. Current Eye Research 1990, 9:323-335.
22. Grant MB, Mames RN, Fitgerald C, Ellis EA, Caballero S, Chegini N, Guy J: Insulin-like growth factor I as an angiogenic agent: in vivo and in vitro studies. Ann NY Acad Sci 1993, 692:230-242.
23. Grant M, Russel B, Fitgerald C, Merimee TJ: Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes 1986, 35:416-420.
24. Dills DG, Moss SE, Klein R, Klein BEK: Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes. Diabetes 1991, 40:1725-1730.
25. Wang Q, Dills DG, Klein R, Klein BEK, Moss SE: Does insulin-like • growth factor 1 predict incidence and progression of diabetic retinopathy. Diabetes 1995, 44:161-164. A carefully performed and detailed evaluation of serum IGF-1 levels, and incidence of retinopathy over a 6-year period in a well-characterized cohort of more than 1000 individuals. No correlation between IGF-1 and incidence or progression of retinopathy was found in any subgroup.
26. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak JF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
27. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF, Science 1989, 246:1309-1312.
28. Leung DW, Cachianes G, Kunang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
29. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991. 47:211-218.
30. Senger D, Connolly D, Vad DeWater L, Feder J, Dvorak H: Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990, 50:1774-1778.
31. Pepper M, Ferrara N, Orci L, Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992, 189:824-831.
32. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
33. Ferrara N, Houck K, Jakeman L, Leung D: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endoc Rev 1992, 13:18-32.
34. Guerrin M, Moukadin H, Chollet P, Moro F, Dutt K, Malecaze F, Plouet J: • Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995, 164:385-394. The first demonstration that VEGF is mitogenic for ocular cell types other than endothelial cells. Two high-affinity VEGF receptors were found on retinal pigment epithelial cells and their proliferation and migration was induced by VEGF.
35. Takagi H, King GL, Aiello LP: Identification and characterization of vas• cular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 1996, 45:1016-1023. Characterization of VEGF receptors on retinal pericytes; an ocular cell of nonendothelial origin. Although VEGF-induced pericyte growth was limited and delayed, tyrosine phosphorylation of several intracellular molecules was noted, suggesting that VEGF may mediate other, as yet unidentified, effects in retinal pericytes.
36. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J, • Yamamoto H: Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995, 270:28316-28324 The first description of VEGF receptors on retinal pericytes in which only Flt1 mRNA was observed, in contrast with the usual two classes of VEGF receptor (Flk and Flt) found on endothelial cells.
37. Kim KJ, Li B, Winer J, Armanini M, Gillette N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362:841-844.
38. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
39. Adamis AP, Shima DT, Yeo K-T, Yeo T-K, Brown LF, Berse B, D'Amore PA, Folkman J: Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993, 193:631-638.
40. Aiello L, Northrup J, Keyt B, Takagi H, Iwamoto M: Hypoxic regulation of • vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995, 113:1538-1544. An evaluation of the hypoxic regulation of three ocular cell types: endothelial cells, pericytes, and pigment epithelial cells. Hypoxia induced VEGF expression in all cells in a dose-dependent and reversible manner. Endothelial cell growth was stimulated by exogenous VEGF and by media conditioned under hypoxic conditions by ocular cells. VEGF neutralizing compounds eliminated both of these responses suggesting VEGF was the primary hypoxia-induced mitogen under these conditions.
41. Yang Q, Zwijsen A, Siegers H, Vanden Berghe D: Purification and characterization of VEGF/VPF secreted by human retinal pigment epithelial cells. Endothelium 1994, 2:73-85.
42. Simorre P, Guerrin M, Chollet P, Penary M, Clamens S, Malecaze F, Plouet J: Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci 1994, 35:3393-3400.
43. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL: Comparative analysis of vascular endothelial growth factor (VEGF) receptors on retinal and aortic microvascular endothelial cells. Diabetes 1994, 44:98-103.
44. Smith L, Wesolowski E, McLellan A, Kostyk S, D'Amato R, Sullivan R: Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994, 35:101-111.
45. Dorey CK, Aouididi S, Reynaud X, Dvorak HF, Brown LF: Correlation of • vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat Arch Ophthalmol 1996, 114:1252-1254. In situ hybridization demonstrated that VEGF mRNA was elevated in the inner nuclear layer of the retina in neonatal rats with oxygen-induced retinal neovascularization. Maximal VEGF expression was observed adjacent to areas of neovascularization.
46. Stone J, Chang-Ling T, Pe're J, Itin A, Gnessin H, Keshet E: Roles of vas• cular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996, 37:290-299. A careful study detailing the sequential role of various ocular cell types, hypoxia, and VEGF in the developing cat and rat retina. Hypoxic regulation of VEGF expression in the intact developing retina was demonstrated by using oxygen-enriched atmospheres that inhibited vessel formation and endogenous VEGF production.
47. Donahue ML, Phelps DL, Watkins RH, LoMonaco MB, Horowitz S: Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen-induced retinopathy. Curr Eye Res 1996, 15:175-184.
48. Pierce EA, Avery R, Foley E, Aiello L, Smith LEH: Vascular endothelial • growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Nat Acad Sci USA 1995, 92:905-909. This study demonstrated that VEGF expression was correlated both temporally and spatially with the onset of ischemia-induced retinal neovascularization in the mouse. Protein localization predominated at Müller-like cells, whereas mRNA expression was primarily found in the inner nuclear retinal layers.
49. Pierce EA, Foley ED, Smith LE: Regulation of vascular endothelial •• growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996, 111:1219-1228. In the mouse model of retinopathy of prematurity, hyperoxic conditions reduced VEGF mRNA and protein expression, and induced vascular loss. Addition of exogenous VEGF salvaged vascular loss despite hyperoxic conditions. Supplemental oxygen, administered after retinal ischemia had already induced VEGF. reduced VEGF expression.
50. Miller JW, Adamis AP, Shima D, D'Amore PA, Moulton R, O'Reilly M, Folk• man J, Brown L, Berse B, Yeo T-K, et al.: Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994, 145:574-584. The first study temporally correlating VEGF with intraocular neovascularization. Iris neovascularization induced by iatrogenic retinal vein occlusion in a primate arose shortly after intraocular VEGF protein concentrations increased and declined, as VEGF levels diminished.
51. Aiello LP, Avery RL, Arrigg PG, Keyt B, Aiello LM, Jampel HD, Shah ST, •• Pasquale LR, Thieme H. Iwamoto MA, et al.: Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. W Engl J Med 1994, 331:1480-1487. Evaluation of 210 intraocular fluid samples from 164 patients (143 from diabetic individuals) demonstrated that both aqueous and vitreous VEGF concentrations were high during active intraocular neovascularization and low at other times. The predicted intraocular concentration gradient and VEGF reduction following successful treatment with laser photocoagulation were also demonstrated.
52. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo T-K, Yeo • K-T: Elevated vascular permeability factor/vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118:445-450. A clinical study demonstrating higher vitreous concentrations of VEGF in 8 patients with proliferative diabetic retinopathy than was detected in 12 patients without diabetes.
53. Malecaze F, Clamens S, Simorre-Pinatel V, Cholleg P, Favard C, Bayard F, • Plouet J: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994, 112:1476-1482. A survey of eight growth factors in neovascular membranes obtained from diabetic patients. Using polymerase chain reaction technology, only VEGF was detected in all samples.
54. Pe'er J, Folberg R, Itin A, Gnessin H, Memo I, Keshet E: Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 1996, 80:241-245.
55. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, •• King GL, Smith LEH: Inhibition of vascular endothelial growth factor suppresses retinal neovascularization in vivo. Proc Natl Acad Sci 1995, 92:10457-10461. VEGF-neutralizing receptor chimeric proteins were injected intravitreally in a murine model of ischemia-induced retinal neovascularization. Retinal neovascularization was suppressed in 95% to 100% of animals evaluated. The inhibition was dose dependent and occurred without detectable toxicity by light microscopic evaluation.
56. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LEH: •• Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci 1996, 93:4851-4856. In the murine model of retinopathy, VEGF antisense phosphorothioate Oligodeoxynucleotides were shown to reduce VEGF protein expression in a dose-dependent manner, resulting in reduction of retinal neovascularization
57. Adamis A, Shima D, Tolentino M, Gragoudas E, Ferrara N, Folkman J, •• D'Amore P, Miller J: Inhibition of VEGF prevent ocular neovascularization in a non-human primate. Arch Ophthalmol 1996, 114:66-71. Iris neovascularization due to iatrogenically induced retinal vein occlusion in the primate was inhibited by every other day intraocular injection of VEGF-neutralizing antibodies. Hypoxic induction of VEGF mRNA was not inhibited.
58. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H: Vascular •• endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995, 27:48-52. The first indirect evidence that VEGF may play a role in diabetic retinal hypermeability. VEGF protein expression and serum albumin extravasation were colocalized using immunohistochemistry in diabetic rats. VEGF expression was increased in diabetic as compared with control retinal.
59. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K: The relations between expression of vascular endothelial growth factor and breakdown of the blood retinal barrier in diabetic rat retinas. Lab Invest 1996, 74:819-825.
60. Vinores SA, Kuchle M, Mahlow J, Chiu C, Green WR, Campochiaro PA: • Blood-ocular barrier breakdown in eyes with ocular melanoma: a potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol 1995, 147:1289-1297. Immunohistochemical identification of extravasated albumin and VEGF colocalization in a large percentage of eyes with blood retinal barrier breakdown from ocular melanoma suggest a role of VEGF in mediating retinal vascular permeability.
61. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatziste•• fanou K, Ferrare N, Adamis AP: Intravenous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996, 103:1820-1828. In the primate, repeated injections of high-concentration VEGF into the normal eye produced vessel tortuosity, veneous beading, capillary abnormalities resembling microaneurysms, intraretinal hemorrhages, capillary closure, and apparent increased in vascular permeability as assessed by fluorescein angiogram.
62. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW: Vascular •• endothelial growth factor is present in the glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Opthalmol Vis Sci 1997, 38:36-47. Immunohistichemical evaluation demonstrated increased levels of VEGF protein in eight postmortem eyes of patients with nonproliferative diabetic retinopathy in the absence of extensive nonperfusion as compared with five nondiabetic controls. These studies suggest that factors other than hypoxia may induce VEGF expression and that VEGF may be involved in the pathogenesis of early diabetic retinopathy.
63. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E: Vascular endothelial •• growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1:1024-1028. Regression of retinal capillaries in neonatal rats was preceded by a reduction in VEGF expression and occurred by selective apoptosis. Intraocular injection of VEGF prevented retinal capillary regression. These studies suggest that VEGF may act as a survival factor in vivo and may be involved in the early stages of retinopathy of prematurity.
64. Manual of Procedures: Multicenter Trial of Supplemental Oxygen for Pre-threshold Retinopathy of Prematurity (STOP-ROP). 1991, NIH Grant #U10 EY09962.
65. Tolentino MJ, Miller JW, Gragoudas ES, Chatzisefanou K, Ferrare N, • Adamis AP: Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996, 114:964-970. High concentrations of VEGF injected into the normal adult primate eye every third day over a 30-day period resulted in neovascularization of the iris, ectropion uvea, and neovascular glaucoma.
66. Lutty GA, McLeod GD, Merges C, Diggs A, Plouet J: Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996, 114:971-977.
67. Kvanta A, Algvere PV, Berglin L, Seregard S: Subfoveal fibrovascular •• membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996, 37:1929-1934. Surgically removed subfoveal fibrovascular membranes from 18 eyes with exudative age-related macular degeneration demonstrated strong expression of both VEGF mRNA and protein by insitu hybridization and immunohistochemistry, respectively.
68. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR: Transdifferenti•• ated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996, 37:855-868. Immunohistochemical analysis of eight surgically excised, age-related, macular degeneration-associated choroidal neovascular membranes revealed that VEGF immunoreactivity was preferentially localized within the cytoplasm of polygonal transdifferentiated retinal pigment epithelial cells in the highly vascularized regions of the membrane.
69. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor •• ZJ: Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularization. Br J Ophthalmol 1996, 80:363-366. VEGF concentrations in the undiluted vitreous fluids of eight patients undergoing surgical removal of nonage-related subfoveal choroidal neovascular membranes were substantially higher than that found in samples from 18 patients with idiopathic full-thickness macular holes, but lower than that found in 16 patients with proliferate diabetic retinopathy.
70. Collis MG, Hourani SMO: Adenosine receptor subtypes. Tips Reviews 1993, 14:360-366.
71. Bontemps F, Mimouni M, Van den Berghe, G: Mechanisms of elevation of adenosine levels in anoxic hepatocytes. J Biochem 1993, 290:671-677.
72. 2 receptors.
73. Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP: Hypoxic induction •• of vascular endothelial growth factor (VEGF) is mediated by adenosine, adenosine A2 receptors and cAMP-dependent protein kinase A in retinal microvascular pericytes and vascular endothelial cells. Invest Opthalmol Vis Sci 1996, 37:2165-2176. Detailed analysis of adenosine modulation of hypoxia-induced VEGF expression in retinal cells. VEGF was shown to bind adenosine A2a receptors, subsequently increasing cAMP and activating protein kinase A, The hypoxic induction of VEGF could be mimicked or suppressed by adenosine A2a receptor agonists and antagonists, respectively.
74. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, • Kim RY, Rohan RM, Colby KA, Yeo KT, et al.: Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996, 98:1667-1675 Superoxide and hydrogen peroxide stimulated VEGF mRNA and protein production in retinal pigment epithelial cells. Antioxidants suppressed the reperfusion-associated VEGF mRNA increase in vivo.
75. Guo D, Jia Q, Song HY, Warren RS, Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains: association with endothelial cell proliferation. J Biol Chem 1994, 270:6729-6733.
76. Waltenberger J, Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269:26988-26996.
77. Pu X, Aiello LP, Jiang ZY, Park DJ, Newsome WP, King GL: Characterizz•• tion of vascular endothelial growth factors effect on the activation of phospholipase Cγ, protein kinase C pathways and endothelial cell growth. J Clin Invest 1996, 98:2018-2026. Detailed analysis of the VEGF signal transduction cascade in endothelial cells, demonstrating that VEGF activates phospholipase C. increases diacylglycerol and inositol triphosphates, and activates and induces translocation of protein kinase C isoforms α and β. The β isoform of PKC was primarily responsible for mediating VEGF-induced mitogenesis.
78. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, Rosenfield K, Weir L, Brogi E, Jurayj D: Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 1996, 20:7:959-988.
79. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield •• K, Razvi S, Walsh K, Symes JF: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348:370-374. Angioplasty administration of 2000 μg of human plasmoid phVEGF165 in a 71-year-old woman with an ischemic right leg resulted in an increase in collateral vessels in the leg. and increased blood flow and leg edema which was treated successfully.
80. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA: Involvement of integrins alpha V beta 3 and alpha V beta 5 in ocular neovascular. Proc Natl Acad Sci USA 1996, 93:9764-9976.
81. Blei F, Wilson EL, Mignatti P, Rifkin DB: Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993, 155:568-578.
82. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082-4085.
83. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal. Natl Med 1996, 2:529-533.
84. Aiello LP: Implications for novel growth factor therapies in diabetic retinopathy. Curr Opin Endocrinology Diabetes 1996, 3:307-314.
85. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla •• TA, Ways K, Jirousek M, et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform selective inhibitor. Diabetes 1997, in press. Intraocular injections of VEGF at concentrations observed clinically resulted in rapid, dose-dependent increases in retinal vascular permeability as assessed by vitreous fluorophotometry in rats. Retinal vascular permeability was increased over threefold by VEGF. Selective inhibition of the β isoform of PKC, however, abolished VEGF's ability to stimulate retinal vascular permeability, even when the inhibitor was administered orally.